Description:
IDSA’s journals Clinical Infectious Diseases (CID), The Journal of Infectious Diseases (JID) and Open Forum Infectious Diseases (OFID) are seeking ID-trained physicians to become associate editors. CID is also seeking ID pharmacists for some associate editor positions. Applications are due no later than March 11, 2022, but will be considered on a rolling basis.
Purpose
IDSA journal associate editors lead the peer review process for manuscripts accepted for review and help determine the content and quality of papers published in the IDSA journals.
Responsibility
Associate editors help review submitted manuscripts, invite peer reviewers for papers of sufficient quality and collaborate with the editor-in-chief and deputy editor(s) on decisions regarding publication. Soliciting original content from colleagues and ID fellows-in-training is also strongly encouraged, as are individual contributions. The associate editors participate in an annual meeting at IDWeek as well as periodic phone conference calls with the other editors. An annual honorarium is provided.
Qualifications
CID is seeking associate editors to join its new editorial board with incoming editor-in-chief Paul Sax, MD, FIDSA. Among areas of interest, CID is seeking editors with expertise in tropical medicine/parasitology, mycobacterial infections, hospital epidemiology/infection control, pediatric ID and immunizations, antimicrobial resistance, STIs, transplant ID, clinical microbiology and general infectious diseases practice. Candidates with broad clinical expertise and experience who can adjudicate the quality of clinical research even outside of their primary areas of focus are particularly encouraged to apply. CID is seeking ID pharmacists (PharmD required) to become associate editors as well. New CID editors would begin training with IDSA’s manuscript submission system in April 2022.
JID is seeking associate editors to join its new editorial board with incoming editor-in-chief Cindy Sears, MD, FIDSA. JID is seeking editors with expertise in basic and translational infectious diseases including antimicrobial resistance, disease mechanisms and pathogenesis across the spectrum of infectious pathogens, international health, vaccine and drug development, novel diagnostics and therapeutics as well as genomics and microbiome science. New JID editors would begin training with IDSA’s manuscript submission system in August 2022.
OFID is seeking associate editors to join its editorial board with expertise in TB/mycobacterial diseases, antimicrobial resistance, clinical microbiology, transplant ID, HIV/SARS-CoV-2/virology and statistics. New OFID editors would join the editorial board immediately, as soon as their appointments are approved.
The editors of CID, JID and OFID are strongly interested in applications from members of underrepresented groups, including women; Black, Indigenous and people of color; Latinx people; and LGBTQ+ people.
The editors of all three journals are open to part-time associate editor appointments for individuals who are interested in an associate editor role but require a reduced workload to balance other commitments.
Composition
To be determined by the editors-in-chief based on the number of manuscript submissions in various topical areas.
Estimated Time Commitment
Approximately 150 hours/year, although the specific time commitment will vary by month and by submissions received in each editor's area of expertise.
Meeting Frequency
The associate editors participate in an annual meeting at IDWeek as well as periodic phone conference calls with the other editors.
Method of Appointment
Associate editors are nominated by the editors-in-chief; those nominations are then reviewed by the Publications Committee and approved by the IDSA Board of Directors.
Term of Office
5 years, with the potential for extension to a second term.
Accountability
The work of the associate editors is overseen by the journal’s editor-in-chief and deputy editor(s).
Staff Liaison
Managing editors of Clinical Infectious Diseases, the Journal of Infectious Diseases, and Open Forum Infectious Diseases.